抗TFAM抗体将线粒体损伤与系统性红斑狼疮中的抗磷脂综合征和血栓形成相关联
在22例系统性红斑狼疮(SLE)患者和9例健康对照中探索发现抗TFAM抗体,后用酶联免疫吸附试验在158例SLE患者和98例健康对照中检测,48/158例SLE患者阳性;抗TFAM抗体与血栓形成(OR 2.9)和抗磷脂综合征(OR 5.4)相关,与疾病活动性或I型干扰素特征无关,并与狼疮抗凝物协同增加血栓风险(OR 8.71)。
要点
- 48/158例SLE患者抗TFAM抗体阳性,该抗体与疾病活动性和干扰素特征无关。
- 抗TFAM抗体与血栓形成(OR 2.9)及抗磷脂综合征(OR 5.4)相关。
- 狼疮抗凝物增加抗TFAM抗体相关血栓风险(OR 8.71),提示独立促血栓通路。
核心结论
- 抗TFAM抗体标识SLE中一个与线粒体损伤、血栓形成和抗磷脂综合征相关的独特临床和转录疾病亚群。
研究设计与样本
- 探索性样本为22例SLE患者和9例健康对照,用于发现抗TFAM抗体。
- 采用酶联免疫吸附试验在98例健康对照和158例SLE患者中检测抗TFAM抗体以明确患病率、临床意义及与转录谱和干扰素水平的关联。
- 同时检测了皮肌炎、类风湿关节炎和原发性抗磷脂综合征患者的血清。
主要发现
- 在分析中性粒细胞自身抗原时发现SLE患者存在抗TFAM抗体,并经酶联免疫吸附试验和免疫印迹确认。
- 48/158例SLE患者抗TFAM抗体阳性。
- 与抗dsDNA抗体不同,抗TFAM抗体与疾病活动性或干扰素特征无关。
- 抗TFAM抗体与血栓形成(OR 2.9)和抗磷脂综合征(OR 5.4)相关,并与血栓形成相关转录谱及干扰素-III升高相关。
- 原发性抗磷脂综合征中也发现抗TFAM抗体;狼疮抗凝物增加抗TFAM抗体相关血栓风险(OR 8.71)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Mitochondria are a source of autoantigens and damage-associated molecular patterns (DAMPs) in systemic lupus erythematosus (SLE). Nucleoids carrying TFAM (transcription factor A, mitochondrial) and mitochondrial DNA (mtDNA) are important DAMPs in SLE. While mtDNA has been associated with anti-double-stranded (ds)DNA antibodies and type I interferon (IFN-I), the immunogenic role of TFAM in SLE pathogenesis is unknown. Here, we characterised the clinical and transcriptional phenotypes linked to anti-TFAM antibodies in SLE. METHODS: Anti-TFAM antibodies were discovered in an exploratory sample of 22 SLE patients and 9 healthy controls. To define the prevalence, clinical significance, and associations with transcriptional profiles and IFN levels, anti-TFAM antibodies were detected using enzyme-linked immunosorbent assay (ELISA) in 98 healthy controls and 158 SLE patients. Sera from patients with dermatomyositis, rheumatoid arthritis, and primary antiphospholipid syndrome (PAPS) were also tested. RESULTS: Anti-TFAM antibodies were discovered in patients with SLE while analysing neutrophil autoantigens and confirmed by ELISA and immunoblotting. One-third of SLE patients (48/158) were positive for anti-TFAM antibodies. Unlike anti-dsDNA antibodies, anti-TFAM antibodies were not associated with disease activity or the IFN signature. Instead, anti-TFAM antibodies were associated with thrombosis, antiphospholipid syndrome (APS) (odds ratio [OR], 2.9 and 5.4, respectively), thrombosis-associated transcriptional profiles, and elevated IFN-III. Anti-TFAM antibodies were also found in PAPS, supporting their role in APS but not SLE pathogenesis. Lupus anticoagulant increased the risk of thrombosis associated with anti-TFAM antibodies (OR, 8.71), indicating they are markers of independent prothrombotic pathways. CONCLUSIONS: Anti-TFAM antibodies identify a distinct clinical and transcriptional disease subset associated with mitochondrial damage, thrombosis, and APS in SLE.
引用
- Gómez-Bañuelos E, Celia AI, Trejo-Zambrano MI, et al. Anti-TFAM antibodies link mitochondrial damage with antiphospholipid syndrome and thrombosis in SLE. Ann Rheum Dis. 2025. PMID: 40350373. doi:10.1016/j.ard.2025.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。